MA28494B1 - Dérivé de pyrazole cristallin - Google Patents

Dérivé de pyrazole cristallin

Info

Publication number
MA28494B1
MA28494B1 MA29353A MA29353A MA28494B1 MA 28494 B1 MA28494 B1 MA 28494B1 MA 29353 A MA29353 A MA 29353A MA 29353 A MA29353 A MA 29353A MA 28494 B1 MA28494 B1 MA 28494B1
Authority
MA
Morocco
Prior art keywords
pyrazole derivative
crystalline
crystalline pyrazole
derivative
pyrazole
Prior art date
Application number
MA29353A
Other languages
English (en)
Inventor
Changquan Calvin Sun
Garry O'connor
Original Assignee
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Co Llc filed Critical Pharmacia & Upjohn Co Llc
Publication of MA28494B1 publication Critical patent/MA28494B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W16/00—Network planning, e.g. coverage or traffic planning tools; Network deployment, e.g. resource partitioning or cells structures
    • H04W16/18—Network planning tools
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W24/00—Supervisory, monitoring or testing arrangements
    • H04W24/02—Arrangements for optimising operational condition

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Signal Processing (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MA29353A 2004-04-01 2006-09-29 Dérivé de pyrazole cristallin MA28494B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US55846904P 2004-04-01 2004-04-01

Publications (1)

Publication Number Publication Date
MA28494B1 true MA28494B1 (fr) 2007-03-01

Family

ID=34961629

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29353A MA28494B1 (fr) 2004-04-01 2006-09-29 Dérivé de pyrazole cristallin

Country Status (24)

Country Link
US (2) US7652149B2 (fr)
EP (1) EP1742922B1 (fr)
JP (1) JP4177883B2 (fr)
KR (1) KR100820511B1 (fr)
CN (1) CN1938276B (fr)
AR (1) AR048449A1 (fr)
AU (1) AU2005227745C1 (fr)
BR (1) BRPI0509506A8 (fr)
CA (1) CA2562104C (fr)
DK (1) DK1742922T3 (fr)
EA (1) EA008697B1 (fr)
ES (1) ES2565409T3 (fr)
HU (1) HUE028811T2 (fr)
IL (1) IL177711A0 (fr)
MA (1) MA28494B1 (fr)
NO (1) NO20064986L (fr)
NZ (1) NZ550907A (fr)
PL (1) PL1742922T3 (fr)
SI (1) SI1742922T1 (fr)
TN (1) TNSN06313A1 (fr)
TW (1) TW200536816A (fr)
UA (1) UA84455C2 (fr)
WO (1) WO2005095349A1 (fr)
ZA (1) ZA200607154B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE028811T2 (en) * 2004-04-01 2017-01-30 Zoetis Services Llc Crystalline pyrazole derivative
WO2007069254A2 (fr) 2005-12-14 2007-06-21 Makhteshim Chemical Works Ltd. Polymorphes et formes amorphes de 5-amino-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-[(trifluoromethyl)sulfinyl]-1h-pyrazole-3-carbonitrile
UA110598C2 (uk) 2006-11-10 2016-01-25 Басф Се Спосіб одержання кристалічної модифікації фіпронілу
US8791046B2 (en) 2006-11-10 2014-07-29 Basf Se Crystalline modification of fipronil
JP5931322B2 (ja) 2006-11-10 2016-06-08 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ フィプロニルの結晶変態
JP2017081860A (ja) * 2015-10-29 2017-05-18 株式会社トクヤマ セレコキシブの製造方法
CN115246790A (zh) * 2021-04-25 2022-10-28 广东东阳光药业有限公司 一种吡唑类化合物的晶型及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69112917T2 (de) * 1990-06-15 1996-05-15 Merck & Co Inc Kristallisationsverfahren zur Verbesserung der Kristallstruktur und -grösse.
US6492411B1 (en) * 1993-11-30 2002-12-10 G. D. Searle & Co. Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
KR19990064310A (ko) * 1995-10-17 1999-07-26 윌리암스 로저 에이 시클로옥시게나제-2의 검출방법
US6083986A (en) * 1996-07-26 2000-07-04 Icagen, Inc. Potassium channel inhibitors
US6221153B1 (en) * 1998-06-09 2001-04-24 Trevor Percival Castor Method for producing large crystals of complex molecules
US6787154B2 (en) * 1998-10-20 2004-09-07 Salvatore Albani Artificial antigen presenting cells
SA99191255B1 (ar) 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
TR200001872A2 (tr) * 2000-06-26 2002-01-21 Fako �La�Lari A.� 4-[5-(4-Metilfenil-3-(triflorometil)-1H-pirazol-1-il] benzensulfonamit' in yeni kristal biçimi "Biçim I" ve bu ürünün üretilmesine ilişkin yöntem.
HUE028811T2 (en) * 2004-04-01 2017-01-30 Zoetis Services Llc Crystalline pyrazole derivative

Also Published As

Publication number Publication date
UA84455C2 (en) 2008-10-27
IL177711A0 (en) 2006-12-31
PL1742922T3 (pl) 2016-06-30
TNSN06313A1 (fr) 2007-12-03
NO20064986L (no) 2006-12-21
KR100820511B1 (ko) 2008-04-11
HUE028811T2 (en) 2017-01-30
AU2005227745C1 (en) 2009-02-26
KR20060131949A (ko) 2006-12-20
EP1742922A1 (fr) 2007-01-17
AR048449A1 (es) 2006-04-26
CN1938276B (zh) 2011-08-10
HK1099755A1 (en) 2007-08-24
JP2007530655A (ja) 2007-11-01
CA2562104A1 (fr) 2005-10-13
AU2005227745A1 (en) 2005-10-13
ZA200607154B (en) 2008-03-26
US20050222240A1 (en) 2005-10-06
US7652149B2 (en) 2010-01-26
JP4177883B2 (ja) 2008-11-05
BRPI0509506A8 (pt) 2017-01-24
AU2005227745B2 (en) 2008-05-29
NZ550907A (en) 2010-10-29
TW200536816A (en) 2005-11-16
CN1938276A (zh) 2007-03-28
EP1742922B1 (fr) 2016-02-03
EA200601601A1 (ru) 2007-02-27
EA008697B1 (ru) 2007-06-29
BRPI0509506A (pt) 2007-09-18
DK1742922T3 (en) 2016-04-11
CA2562104C (fr) 2010-08-17
SI1742922T1 (sl) 2016-07-29
US20100093820A1 (en) 2010-04-15
WO2005095349A1 (fr) 2005-10-13
ES2565409T3 (es) 2016-04-04

Similar Documents

Publication Publication Date Title
ATE517886T1 (de) Pyrazolderivate
IS8578A (is) 3- karbamoýl - 2- pýridón afleiður
ATE553079T1 (de) Heteroarylphenylharnstoffderivat
EP1958592A4 (fr) Cristallin artificiel
DK1725553T3 (da) Tetrahydropyridoindolderivater
ATE540935T1 (de) Chinazolinderivate
DK1919907T5 (da) Heterocyklisk forbindelse
EP1724267A4 (fr) Derive de pyrimidine
ATE383361T1 (de) Pyrrazolopyrimidinderivate
EP1988083A4 (fr) Dérivé de triazole
IL183140A0 (en) Substituted benzoquinolizine derivatives
ATE513470T1 (de) Kristalline fipronil-modifikation
IL184841A0 (en) Substituted aminoalkyl-and amidoalkyl-benzopyran derivatives
ATE417830T1 (de) Sulfonylbenzimidazolderivate
ATE510823T1 (de) Fungizide pyridinyloxysubstituierte phenylamidinderivate
DE602006010581D1 (de) 4-phenyl-6-substituierte pyrimidin-2-carbonitrilderivate
ATE404546T1 (de) Substituierte n-sulfonylaminobenzyl-2- phenoxyacetamidverbindungen
IL180889A0 (en) Pyrazole derivative
ATE485294T1 (de) Azaindol-2-carboxamid-derivate
ATE430142T1 (de) Phenylpiperazin-methanon-derivate
ATE527255T1 (de) Aryl-isoxazol-4-yl-imidazol-derivate
DK1971588T3 (da) Tiglien-3-onderivater
ATE404542T1 (de) 4-phenylpyrimidin-2-carbonitrilderivate
MA28494B1 (fr) Dérivé de pyrazole cristallin
ATE365731T1 (de) 4-amino-5-cyanopyrimidinderivate